Skip to main content
. 2023 Sep 8;13(11):2339–2355. doi: 10.1158/2159-8290.CD-23-0383

Figure 4.

Figure 4. Combinations of SHP2 with immune checkpoint inhibitors currently tested in the clinic (top). Schematic model of the changes occurring in the tumor microenvironment upon modulation of SHP2 activity (bottom). Created with BioRender.com.

Combinations of SHP2 with immune checkpoint inhibitors currently tested in the clinic (top). Schematic model of the changes occurring in the tumor microenvironment upon modulation of SHP2 activity (bottom). Created with BioRender.com.